Frequently asked questions

There is a specific set of eligibility criteria you must meet prior to taking part in the trial. You need to contact the site to determine if you can be screened to take part in the clinical trial. Contact details can be found here.

You will not receive any payment for your child taking part in this study. You will not have any additional charge for taking part in this study. Any standard of care procedures (such as blood draws, MRIs, clinical visits, intraventricular infusions) will be billed to you or your insurance.

The only trial site is in Houston, Texas, USA. 

The investigator at the study site will assess your eligibility against the clinical trial protocol. This is to determine if you are eligible to be entered into the trial. 

You may experience side effects if you take part in this study. Before entering the trial, you will need to read a document which outlines the details of the clinical trial including the risks associated with the study drug, the surgery and the procedures you will undergo. If you have any questions, you will have an opportunity to speak to the doctor. You will not undergo any procedure until you have read and signed the document. 

You will read and sign a document which describes the trial in detail. You will not undergo any procedure until you have read and signed the document. You will then undergo a number of procedures to determine whether you are eligible for the study. This includes blood tests, scans and some clinical assessments. If eligible, you may undergo surgery to remove all or part of the tumor and be fitted with a special catheter typically called an Ommaya reservoir. You will then need to return for injections and assessments over a period of six weeks. You will have an MRI scan to assess your disease status.

The treatment will stretch for 6 weeks after surgery or enrollment onto the trial. You will need to visit the hospital site for 4 days (3 rest days) weekly for assessments and injections of MTX110.

Patients with primary (or newly diagnosed) medulloblastoma are unfortunately not eligible to participate in this study. If you have just been diagnosed with medulloblastoma, please speak with your treating physician about your treatment options.